Substance abuse in schizophrenia: Biological factors mediating comorbidity and the potential role of atypical antipsychotic drugs

Substance Abuse in the Mentally and Physically Disabled

Volumn , Issue , 2001, Pages 77-102

  Lee, Myung A ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4344718314     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (156)

1. DA Regier, ME Farmer, DS Rae, BZ Locke, SJ Keith, LL Judd, FK Goodwin. Cormorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 264: 2511-2518, 1990.
2. L Dixon, G Haas, PJ Weiden, J Sweeney, AJ Frances. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148: 224-230, 1991.
3. IL Fowler, VJ Carr, NT Carter, TJ Lewin. Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bull 24: 443-455, 1998.
4. JG Barbee, PD Clark, MS Crapanzano, GC Heintz, CE Kethoe. Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service. J Nerv Ment Dis 177: 400-407, 1989.
5. KT Mueser, PR Yarnod, DF Levinson, H Singh, AS Bellack, K Lee, RL Morrison, KG Yadalam. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bull 16: 31-56, 1990.
6. BJ Cuffel, KA Heithoff, W Lawson. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp Community Psychiatry 44: 247-251, 1993.
7. BJ Cuffel. Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180: 589-592, 1992.
8. BJ Cuffel, P Chase. Remission and relapse of substance use disorders in schizophrenia: results from a one-year prospective study. J Nerv Ment Dis 182: 342-348, 1994.
9. SJ Bartels, RE Drake, MA Wallach. Long-term course of substance use disorder among patients with severe mental illness. Psychiatr Serv 46: 248-251.
10. JR Hughes, DK Hatsukami, JE Mitchell, LA Dahlgren. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993-997, 1986.
11. DM Ziedonis, TR Kosten, WM Glazer, RJ Frances. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 45: 204-206, 1994.
12. J de Leon. Smoking and vulnerability for schizophrenia. Schizophrenia Bull 22: 405-409, 1996.
13. GW Dalack, DJ Healy, JH Meador-Woodruff. Nicotine dependence in schizophrenia: clinical phemomena and laboratory findings. Am J Psychiatry 155: 1490-1501, 1998.
14. MC Fiore, P Newcombe, P McBride. Natural history and epidemiology of tobacco use and addiction. In Nicotine Addiction: Principles and Management. CT Orleans, J Slade, eds. New York: Oxford University Press, pp 89-104, 1993.
15. FT Miller, JH Tanenbaum. Drug abuse in schizophrenia. Hosp Community Psychiatry 40: 847-849, 1989.
16. P J Duke, C Pantelis, TRE Barnes. South Westminster schizophrenia survey: alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 64: 630-636, 1994.
17. PA LeDuc, G Mittleman. Schizophrenia and psychostimulant abuse: a review and reanalysis of clinical evidence. Psychopharmacology 121: 407-427, 1995.
18. FR Schneier, SG Siris. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 175: 641-650, 1987.
19. MT Tsuang, MJ Lyons, JM Meyer, T Doyle, SA Eisen, J Goldberg, W True, N Lin, R Toomey, L Eaves. Co-occurrence of abuse of different drugs in men: The role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 55: 967-972, 1998.
20. RE Drake, FC Osher, MA Wallach. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis 177: 408-414, 1989.
21. M Shumway, TL Chouljian, WA Hargreaves. Patterns of substance use in schizophrenia: a Markov modeling approach. J Psychiatr Res 28: 277-287, 1994.
22. MR Serper, M Alpert, NA Richardson, S Dickson, MH Allen, A Werner. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry 152: 1464-1469, 1995.
23. K Brady, R Anton, JC Ballenger, RB Lydiard, B Adinoff, J Selander. Cocaine abuse among schizophrenic patients. Am J Psychiatry 147: 1164-1167, 1990.
24. P Lysaker, M Bell, J Beam-Goulet, R Milstein. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 182: 109-112, 1994.
25. JP Seibyl, SL Satel, D Anthony, SM Southwick, JH Krystal, DS Charney. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 181: 31-37, 1993.
26. D Kozaric-Kovacic, V Folengovic-Šmale, Z Folengovic, A Marušic. Influence of alcoholism on the prognosis of schizophrenic patients. J Stud Alcohol 56: 622-627, 1995.
27. FC Osher, RE Drake, DL Noordsy, GB Teague, SC Hurlbut, JC Biesanz, MS Beaudett. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. J Clin Psychiatry 55: 109-113, 1994.
28. DH Linszen, PM Dingemans, ME Lenior. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51: 273-279, 1994.
29. KT Brady, T Killeen, P Jarrell. Depression in alcoholic schizophrenic patients. Am J Psychiatry 150: 1255-1256, 1993.
30. SJ Bartels, RE Drake, GJ McHugo. Alcohol abuse, depression, and suicidal behavior in schizophrenia. Am J Psychiatry 149: 394-395, 1992.
31. DC Goff, DC Henderson, BS Amico. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194, 1992.
32. LJ Cohen, MA Test, RL Brown. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 147: 602-607, 1990.
33. P Räsänen, J Tiihonen, M Isohanni, P Rantakallio, J Lehtonen, J Moring. Schizophrenia, alcohol abuse, and violent behavior: a 26-year followup study of an unselected birth cohort. Schizophrenia Bull 24: 437-441, 1998.
34. ME Rice, T Harris. Psychopathy, schizophrenia, alcohol abuse and violent recidivism. Int J Law Psychiatry 18: 333-342, 1995.
35. B Kirkpatrick, XF Amador, M Flaum, SA Yale, JM Gorman, WT Carpenter, M Tohen, T McGlasham. The deficit syndrome in the DSM-IV field trial. I: Alcohol and other drug abuse. Schizophrenia Res 20: 69-77, 1996.
36. S Zisook, R Heaton, J Moranville, J Kuck, T Jernigan, D Braff. Past substance abuse and clinical course of schizophrenia. Am J Psychiatry 149: 552-553, 1992.
37. SC Sonne, KT Brady, WA Morton. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 182: 349-352, 1994.
38. B Kovasznay, J Fleischer, M Tanenberg-Karant, L Jandorf, AD Miller, E Bromet. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bull 23: 195-201, 1997.
39. JE Overall, DR Gorham. The brief psychiatric rating scales. Psychological Reports 10: 799-812, 1962.
40. NC Andreasen. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1983.
41. NC Andreasen. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1981.
42. L Dixon, PJ Weiden, G Haas, J. Sweeney, AJ Frances. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 33: 121-122, 1992.
43. A Zaretsky, NA Rector, MV Seeman, X Fornazzari. Current cannabis use and tardive dyskinesia. Schizophrenia Res 11: 3-8, 1993.
44. WC Wirshing, J Engle, E Levin, JL Cummings, J Rose. The acute effects of smoking on tardive dyskinesia. In New Research Program and Abstracts. Washington, DC: American Psychiatric Association, p 89, 1989.
45. R Sandyk. Cigarette smoking: effects in cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Intern J Neurosci 70: 193-197, 1993.
46. V Dhopesh, A Macfadden, I Maany, G Gamble. Absence of parkinsonism among patients in long-term neuroleptics therapy who abuse cocaine. Psychiatr Serv 48: 95-97, 1997.
47. AM Hegarty, RB Lipton, AE Merriam, K Freeman. Cocaine as a risk factor for acute dystonic reaction. Neurology 41: 1670-1672, 1991.
48. S Sevy, SR Kay, LA Opler, HM van Praag. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 178: 642-648, 1990.
49. SJ Nixon, HG Hallford, RD Tivis. Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Psychiatry Res 64: 35-45, 1996
50. J Addington, D Addington. Substance abuse and cognitive functioning in schizophrenia. J Psychiatry Neurosci 22: 99-104, 1997.
51. JT Kenney, HY Meltzer. Attention and higher cortical functions in shcizophrenia. J Neuropsychiatry 3: 269-275, 1991.
52. J Addington, V Duchak. Reasons for substance use in schizophrenia. Acta Psychiatr Scand 96: 329-333, 1997.
53. MF Brunette, KT Mueser, H Xie, RE Drake. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 185: 13-20, 1997.
54. LNP Voruganti, RJ Heslegrave, AG Awad. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 185: 463-465, 1997.
55. E Hamera, JK Schneider, S Deviney. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. J Nerv Ment Dis 183: 559-565, 1995.
56. J Smith, S Hucker. Schizophrenia and substance abuse. Br J Psychiatry 165: 13-21, 1994.
57. JA Selzer, JA Lieberman. Schizophrenia and substance abuse. Psychiatr Clin North Am 16: 401-412, 1993.
58. KT Mueser, AS Bellack, JJ Blanchard. Comorbidity of schizophrenia and substance abuse: implication for treatment. J Consult Clin Psychol 60: 845-856, 1992.
59. JA Lieberman, BB Sheitman, BJ Kinon. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17: 205-229, 1997.
60. J Altman, BJ Everitt, S Glautiern, A Markou, D Nutt, R Oretti, GD Phillips, TW Robbins. The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology 125: 285-345, 1996.
61. RA Wise, DC Hoffman. Localization of drug reward mechanisms by intracranial injections. Synapse 10: 247-263, 1992.
62. TW Robbins, M Cador, JR Taylor, BJ Everitt. Limbic-striatal interactions in reward-related processes. Neurosci Biobehav Rev 13: 155-162, 1989.
63. T Nishikawa, N Mataga, M Takashima, M Toru. Behaviorial sensitization and relative hyperresponsivness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 88: 195-203, 1983.
64. RC Pierce, PW Kalivas. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25: 192-216, 1997.
65. PA LeDuc, G Mittleman. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology 110: 427-436, 1993.
66. PW Kalivas, S Taylor, JS Miller. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. I. Behavorial characterization. J Pharmacol Exp Ther 235: 537-543, 1985.
67. PW Kalivas. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. II. Involvement of the mesolimbic dopamine system. J Pharmacol Exp Ther 235: 544-550, 1985.
68. EM Pich, SR Pagliusi, M Tessari, D Talabot-Ayer, RH van Huijsduijnen, C Chiamulera. Common neural substrates for the addictive properties of nicotine and cocaine. Science 275: 83-86, 1997.
69. KR Goldstein, DJ Knapp, EI Saiff, LA Pohorecky, D. Benjamin. Sensitization to ethanol demonstrated in place-preference and locomotor activation. Soc Neurosci Abstr 18: 107, 1992.
70. G Di Chiara, A Imperato. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278, 1988.
71. FE Pontieri, G Tanda, F Orzi, G Dichiara. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257, 1996.
72. JA Lieberman, JM Kane, J Alvir. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91: 415-433, 1987.
73. RMG Norman, AK Malla. Stressful life events and schizophrenia. I: A review of the research. Br J Psychiatry 162: 161-166, 1993.
74. H Anisman, R Zachark. Depression: the predisposing influence of stress. Behav Brain Sci 5: 89-137, 1982.
75. C Hammen, M Gitlin. Stress reactivity in bipolar patients and its relation to prior history of disorder. Am J Psychiatry 154: 856-857, 1997.
76. A Breier, OR Davis, RW Buchanan, LA Moricle, RC Munson. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia: relationship to prefrontal cortex volume. Arch Gen Psychiatry 50: 541-550, 1993.
77. I Elman, CM Adler, AK Malhotra, C Bir, D Pickar, A Breier. Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia. Am J Psychiatry 155: 979-981, 1998.
78. C Altamura, G Guercetti, M Percudani. Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Res 30: 69-75, 1989.
79. HY Meltzer. Dopamine, serotonin and glucocorticoids and the psychopathology of schizophrenia. In Schizophrenia. Alfred Benzon Symposium 38. R Fog, J Gerlach, R Hemmingsen, eds. Copenhagen: Munksgaard, pp 74-91, 1995.
80. R Tandon, C Mazzara, J DeQuardo, KA Graig, JH Meaddor-Woodruff, R Goldman, JF Greden. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 29: 953-964, 1991.
81. HY Meltzer, MA Lee, K Jayathilake. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology 2001 (in press).
82. MC Mokrani, F Duval, MA Crocq, PE Bailey, JP Macher. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology 20: 365-375, 1995.
83. DR Weinberger, BK Lipska. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground. Schizophrenia Res 16: 87-110, 1995.
84. D Diorio, V Viau, MJ Meaney. The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci 13: 3839-3847, 1993.
85. AY Deutch, WA Clark, RH Roth. Prefrontal cortical dopamine depletion enchances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res 521: 311-315, 1990.
86. H Verdoux, JR Geddes, N Takei, SM Lawrie, P Bovet, JM Eagles, R Heun, RG McCreadie, TF McNeil, E O’Callaghan, G Stober, MU Willinger, P Wright, RM Murray. Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am J Psychiatry 154: 1220-1227, 1997.
87. WG Brake, MB Noel, P Boksa, A Gratton. Influence of perinatal factors on the nucleus accumbens dopamine response to repeated stress during adulthood: an electrochemical study in the rat. Neuroscience 77: 1067-1076, 1997.
88. M Laruelle, A Abi-Dargham, CH van Dyck, R Gil, CD D’Souza, J Erdos, E McCance, W Rosenblatt, C Fingado, SS Zoghbi, RM Baldwin, JP Seibyl, JH Krystal, DS Charney, RB Innis. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240, 1996.
89. A Breier, T-P Su, R Saunders, RE Carson, BS Kolachana, A deBartolomeis, DR Weinberger, N Weisenfeld, AK Malhotra, WC Eckelman, D Pickar. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomograph method. Proc Natl Acad Sci USA 94: 2569-2574, 1997.
90. JA Lieberman, J Alvir, S Geisler, J Ramos-Lorenzi, M Woerner, H Novarenko, T Cooper, JM Kane. Methylpheridate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 11: 107-118, 1994.
91. DP Van Kammen, JP Docherty, SR Marder, JN Royner, WE Bunney Jr. Longterm pimozide treatment differentially affects behavioral responses to dextroamphetamine in schizophrenia: further exploration of the dopamine hypothesis of schizophrenia. Arch Gen Psychiatry 39: 275-281, 1982.
92. PV Piazza, JM Deminiere, M Le Moal, H Simon. Stress- and pharmacologically induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res 514: 22-26, 1990.
93. V Deroche, M Marinelli, S Maccari, M Le Moal, H Simon, PV Piazza. Stress-induced sensitization and glucocorticooids. I. Sensitization of dopaminedependent locomotor effects of amphetamine and morphine depends on stressinduced corticosterone secretion. J Neurosci 15: 7181-7188, 1995.
94. F Rouge-Pont, M Marinelli, M Le Moal, H Simon, PV Piazza. Stress-induced sensitizaion and glucocorticoid. II. Sensitization of the increase in extracellular dopamine induced by cocaine depends on stress-induced corticosterone secretion. J Neurosci 15: 7189-7195, 1995.
95. PV Piazza, F Rouge-Pont, V Deroche, S Maccari, H Simon, M Le Moal. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci USA 93: 8716-8720, 1996.
96. H Silver, E Abboud. Drug abuse in schizophrenia: comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophrenia Res 13: 57-63, 1994.
97. M Hambrecht, H Hafner. Substance abuse and the onset of schizophrenia. Biol Psychiatry 40: 1155-1163, 1996.
98. S Andreasson, P Allebeck, A Engstrom, V Rydberg. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet ii: 1483-1485, 1987.
99. AY Tien, JC Anthony. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 178: 473-480, 1990.
100. P Allebeck, C Adamsson, A Engstrom, U Rydberg. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand 88: 21-24, 1993.
101. PK McGuire, P Jones, I Harvey, M Williams, P McGuffin, RM Murray. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Res 15: 277-281, 1995.
102. SL Verma, I Sharma. Psychiatric morbidity in the first-degree relatives of schizophrenic patients. Br J Psychiatry 162: 672-678, 1993.
103. PA Fried. Prenatal exposure to marihuana and tobacco during infancy, early and middle childhood: effects and an attempt at synthesis. Arch Toxicol Suppl 17: 233-260, 1995.
104. KS Kendler, CA Prescott. Cannabis use, abuse, and dependence in a populationbased sample of female twins. Am J Psychiatry 155: 1016-1022, 1998.
105. KR Merikangas, M Stolar, DE Stevens, J Goulet, MA Preisig, B Fenton, H Zhang, SS O’Malley, BJ Rounsaville. Familial transmission of substance use disorders. Arch Gen Psychiatry 55: 973: 981, 1998.
106. KS Kendler, L Karkowski-Shuman, D Walsh. The risk for psychiatric illness in siblings of schizophrenics: the impact of psychotic and non-psychotic affective illness and alcoholism in parents. Acta Psychiatr Scand 94: 49-55, 1996.
107. N Lin, SA Eisen, JF Scherrer, J Goldberg, WR True, NJ Lyons, MT Tsuang. The influence of familial and non-familial factors on the association between major depression and substance abuse/dependence in 1874 monozygotic male twin pairs. Drug Alcohol Depend 43: 49-55, 1996.
108. DC D’Souza, A Belger, L Zimmerman, S Adams, R Gil, M Sernyak, JH Krystal. Cannabinoid sensitivity in schizophrenia: dose-response of tetrahydrocannabinol effects in schizophrenics and healthy controls [abstr]. Proceedings of the 36th Annual Meeting of the American College of Neuropsychopharmacology, Kona, HI. P 286, 1997.
109. E Zuzarte, DC D’Souza, R Gil, A Genovese, L Trevisan, J White, DS Charney, JH Krystal. Dose-related ethanol effects in schizophrenic patients [abstr]. Alcohol Clin Exp Res 21(133A): 779, 1997.
110. J Souilhac, M Poncelet, M Rinaldi-Carmona, G Le Fur, P Soubrie. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 51: 3-7, 1995.
111. A Giuffrida, LH Parsons, TM Kerr, F Rodriguez de Fonseca, M Navarro, D Piomelli. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363, 1999.
112. C Castellano, S Cabib, A Palmisano, V DiMarzo, S Puglisi-Allegra. The effects of amandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors. Behav Pharmacol 8: 707-712, 1997.
113. ES Deneris, J Connoly, SW Rogers, R Duvoisin. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci 12: 34-40, 1991.
114. P Séguéla, J Wadiche, K Dineley-Miller, JA Dani, JW Patrick. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13: 596-604, 1993.
115. R Freedman, M Hall, LE Adler, S Leonard. Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22-33, 1995.
116. MC Waldo, E Cawthra, LE Adler, S Dubester, M Staunton, HT Nagamoto, N Baker, A Madison, J Simon, A Scherzinger, C Drebing, G Gerhardt, R Freedman. Auditory sensory gating, hippocampal volume, and catecholamine metabolism and schizophrenics and their siblings. Schizophrenia Res 12: 93-106, 1994.
117. MC Waldo, G Carey, M Myles-Worsley, E Cawthra, LE Adler, HT Nagamoto, P Wender, W Byerley, R Plaetke, R Freedman. Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res 39: 257-268, 1991.
118. LE Adler, LD Hoffer, A Wiser, R Freedman. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861, 1993.
119. LE Adler, LJ Hoffer, J Griffith, MC Waldo, R Freedman. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32: 607-616, 1992.
120. HT Nagamoto, LE Adler, RA Hea, JM Griffith, KA McRae, R Freedman. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 40: 181-188, 1996.
121. TP George, MJ Sernyak, DM Ziedonis, SW Woods. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56: 344-346, 1995.
122. J McEvoy, O Freudenreich, M McGee, C Vander Zwaag, E Levin, J Rose. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 37: 550-552, 1995.
123. LE Adler, GA Gerhardt, R Franks, N Baker, H Nagamoto, C Drebing, R Freedman. Sensory physiology and catecholamine in schizophrenia and mania. Psychiatry Res 31: 297-309, 1990.
124. JP McEvoy, O Frendenreich, ED Levin, JE Rose. Haloperidol increased smoking in patients with schizophrenia. Psychopharmacology (Berl) 119: 124-126, 1995.
125. P Buckley, P Thompson, L Way, HY Meltzer. Substance abuse among patients with reatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 151: 385-389, 1997.
126. RR Conley, DL Kelly, EA Gale. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophrenia Res 33: 95-101, 1998.
127. J Gauldi. The causality of depression in schizophrenia. Br J Psychiatry 142: 621-624, 1983.
128. Collaborative Working Group on Clinical Trial Evaluations. Assessing the effects of atypical antipsychotics on negative symptoms. J Clin Psychiatry 59(suppl 12): 28-34, 1998.
129. Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 59:(suppl 12): 41-45, 1998.
130. J Arnt, T Skarsfeldt. Do novel antipsychotics have similar pharmacological characteristics?: a review of the evidence. Neuropsychopharmacology 18: 63-101, 1998.
131. S Dawe, C Gerada, MAH Russell, JA Gray. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl) 117: 110-115, 1995.
132. P Weiden, R Aguila, J Standard. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 57: 53-60, 1996.
133. HY Meltzer, P Cola, L Way PA Thompson, B Bastani, MA Davis, B Snitz. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 150: 1630-1638, 1993.
134. HY Meltzer, G Okayli. The reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183-190, 1995.
135. MJ Albanese, EJ Khantzian, SL Murphy, AI Green. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 151: 780-781, 1994.
136. Y Yovell, LA Opler. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis 182: 591-592, 1994.
137. ML Lee, RA Dickson, M Campbell, J Oliphant, H Gretton, JT Dalby. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatary 43: 855-856, 1998.
138. DA Smelson, A Roy, M Roy. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry 42: 984, 1997.
139. L Misra, L Kofoed. Risperidone in the treatment of methamphetamine psychosis. Am J Psychiatry 154: 1170, 1997.
140. DA Smelson, A Roy, M Roy. Risperidone and neuropsychological test performance in cocaine-withdrawn patients. Can J Psychiatry 42: 431, 1997.
141. 2-like dopamine receptor agonists. Science 271: 1586-1589, 1996.
142. 2 agonist DOI. Eur J Pharmacol 221: 121-127, 1992.
143. 1A agonist, 8-OH-DPAT. Neuropharmacology 33: 335-342, 1994.
144. 1A receptors in rat hypothalamus and dentate gyrus after “binge” pattern cocaine administration. Synapse 30: 166-171, 1998.
145. A Newman-Tancredi, S Gavaudan, C Conte, C Chaput, M Touzard, L Verriele, V Audinot, MJ Millan. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355: 245-256, 2998.
146. H Rollema, Y Lu, AW Schmidt, SH Zorn. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor action. Eur J Pharmacol 338: R3-5, 1997.
147. TA Kosten, EJ Nestler. Clozapine attenuates cocaine conditioned place preference. Life Sci 55: PL 9-14, 1994.
148. KE Vanover, MF Piercey, WL Woolverton. Evaluation of the reinforcing and discriminative stimulus effects of cocaine in combination with (+)-AJ76 or clozapine. J Pharmacol Exp Ther 266: 780-789, 1993.
149. EA Loh, T Fitch, G Vickers, DCS Roberts. Clozapine increases breaking points on a progressive-ratio schedule reinforced by intravenous cocaine. Pharmacol Biochem Behav 42: 559-562, 1992.
150. RD Myers, MF Lankford. Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone. Neuropsychopharmacology 14: 139-149, 1996.
151. 2 antagonists amperozide and trazodone on preference for alcohol in rats. Alcohol 11: 203-206, 1994.
152. 2 antagonist, attenuates craving for cocaine by rats. Pharmacol-Biochem-Behav 46: 125-129, 1993.
153. JW Tsuang, AP Ho, TA Eckman, A Shaner. Dual diagnosis treatment for patients with schizophrenia who are substance dependent. Psychiatr Serv 48: 887-889, 1997.
154. S Hansell. Treatment for comorbid schizophrenia and substance abuse disorders. New Direction for Mental Health Services 73: 65-73, 1997.
155. AL Hoff, H Riordan, DW O’Donnell, L Morris, LE DeLisi. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 149: 898-903, 1992.
156. AJ Saykin, DL Shtasel, RE Gur, DB Kester, LH Mozley, P Stafiniak, RC Gur. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-131, 1994.